SB-01 is under clinical development by Spine BioPharma and currently in Phase III for Low Back Pain. According to GlobalData, Phase III drugs for Low Back Pain have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SB-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SB-01 overview

SB-01 is under development for the treatment of degenerative disc disease (DDD) and low back pain. The drug candidate is administered as an intradiscal injection. It is a synthetic peptide and targets TGF beta 1. It is developed based on knowledge-based in silico drug discovery platform called KISDD.

Spine BioPharma overview

Spine BioPharma is a developer of a non-surgical solution that will remove pain and restore functionality. Spine BioPharma is headquartered in New York City, New York, the US.

For a complete picture of SB-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.